Four months after House Speaker Nancy Pelosi declared “We have to pass the bill so you can find out what’s in it,” a congressional panel has released the first chart illustrating the 2,801 page health care law President Obama signed into law in March. Check out the video…
In this video interview, Oncology board member and CancerNetwork contributing editor, Derek Raghavan, MD, PhD, Institute Chair, Taussig Cancer Institute gives his opinion on how the changing landscape of the American healthcare system will affect cancer care.
This year’s “Cancer Trends” survey provides insight into ambulatory cancer care, effects of the recession, and organizational strategies that may help providers adapt to the changes in the healthcare marketplace.
Medicare is now questioning whether the government should pay for new therapy's such as Provenge. The CMS decision is just as important to the biopharmaceutical industry, doctors, and their patients as it is to Dendreon. H. R. 4732, The Compassionate Access Act, calls to give access to novel drugs;will CMS serve as a roadblock?
This is decision time at FDA. Since the agency gave accelerated approval for Avastin in first-line treatment of metastatic breast, two follow-up studies “failed to confirm the magnitude” of the benefits seen in that first study of Avastin. Consequently, ODAC voted 12 to 1, urging FDA to reverse its approval of Avastin in this indication.
Most busy oncologists will never have time or patience to sift through the 864-page final rule CMS released Tuesday describing how health care providers can demonstrate "meaningful use" of electronic health records to qualify for Medicare and Medicaid incentive payments under the 2009 federal stimulus package.
Prostate cancer is one of the leading causes of death from malignant disease among men in the developed world. The extent of benefit and harm with widespread PSA screening is under continuous debate.
As covered in the RPM Report, CMS announced June 30 that it had opened a national coverage analysis (NCA) for Provenge to determine whether the therapy is “reasonable and necessary.”
The Eleventh Lung Cancer Congress will be held July 8-11, 2010 in Rancho Palos Verdes, California
In our experience, EMRs are not working, and we need a different solution. Fast. Here are just three of the problems. In our opinion, Medicare needs to stop the train at the station until some other important issues are addressed that enable EMR to be effective.